查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1575464

子宫内膜异位症药物市场：按药物类型、给药途径、患者特征和最终用户划分 - 全球预测 2025-2030

Endometriosis Drugs Market by Drug Type, Route Of Administration, Patient Demographics, End-User - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 187 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2023年子宫内膜异位症药物市值为25.4亿美元，预计2024年将达到26.9亿美元，复合年增长率为7.11%，2030年将达到41.1亿美元，预计将达到1000万美元。

子宫内膜异位症药物市场涵盖一系列用于治疗与子宫内膜异位症相关的疼痛和其他症状的药物治疗，子宫内膜异位症是一种类似于子宫内膜的组织在子宫外生长的疾病。根据卫生组织的数据，子宫内膜异位症影响全球约 10% 的育龄妇女，因此这些药物至关重要，因为子宫内膜异位症具有慢性且常常使人衰弱的性质。这些药物主要用于减少发炎、缓解疼痛和缓解荷尔蒙失衡。主要最终用户包括医院、诊所和家庭护理机构，患者在这些场所寻求医疗干预以管理症状。市场成长的关键因素包括子宫内膜异位症盛行率的增加、认识和诊断率的提高以及口服促性腺激素分泌释放激素拮抗剂等药物开发技术的进步。此外，政府对妇女健康措施的支持和投资正在创造新的机会。公司可以透过专注于早期检测技术和个人化医疗方法来投资资本，从而提供潜在的生产力提升和患者满意度。然而，药物成本高、非侵入性治疗的可用性有限以及潜在的副作用等限制构成了重大挑战。此外，新兴国家的认知度较低继续限制市场渗透。创新领域包括开发副作用较少的生物同质激素，以及使用数位健康技术进行早期诊断和治疗监测。对免疫调节和血管生成抑制剂等替代疗法的研究可能为进一步发展指明道路。这个市场竞争激烈，製药巨头投资研发，同时提供利基解决方案的新兴企业不断涌现。为了保持竞争力，公司必须与进行前沿研究的学术机构合作，并维持以患者为中心的研发，以确保治疗方法可及且负担得起。

主要市场统计
基准年[2023] 25.4亿美元
预测年份 [2024] 26.9亿美元
预测年份 [2030] 41.1亿美元
复合年增长率（%） 7.11%

市场动态：揭示快速发展的子宫内膜异位症药物市场的关键市场洞察

子宫内膜异位症药物市场正因供需的动态交互作用而转变。了解这些不断变化的市场动态可以帮助企业做出明智的投资决策、策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，同时消费行为及其对製造成本的影响以及对采购趋势的影响。

  • 市场驱动因素
    • 政府对妇女健康计画的承诺和支持，以促进子宫内膜异位症的治疗
    • 提高子宫内膜异位症微创治疗的可用性和可及性
    • 提高患者对更好的子宫内膜异位症治疗方案的认识和宣传
    • 扩大远距远端医疗和数位健康平台以推进子宫内膜异位症管理
  • 市场限制因素
    • 子宫内膜异位症治疗方法相关的经济障碍和高成本
    • 耻辱感和缺乏认识导致子宫内膜异位症患者诊断和治疗的延误
  • 市场机会
    • 奈米技术标靶给药系统在子宫内膜异位症治疗的应用
    • 加大子宫内膜异位症新药研发投入
    • 扩大医疗保健政策以涵盖创新的子宫内膜异位症治疗和疗法
  • 市场挑战
    • 全球监管合规挑战影响新子宫内膜异位症药物的市场准入
    • 供应链中断导致药物短缺和子宫内膜异位症医疗管理成本增加

波特五力：驾驭子宫内膜异位症药物市场的策略工具

波特的五力框架是理解市场竞争格局的重要工具。波特的五力框架为评估公司的竞争地位和探索策略机会提供了清晰的方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点并避免潜在的挑战，从而确保更强大的市场地位。

PESTLE分析：了解子宫内膜异位症药物市场的外部影响

外部宏观环境因素在塑造子宫内膜异位症治疗药物市场的绩效动态方面发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并为他们做出积极主动的决策做好准备。

市场占有率分析 了解子宫内膜异位症治疗药物市场的竞争状况

子宫内膜异位症治疗药物市场的详细市场占有率分析可以对供应商的绩效进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、分散和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

FPNV 定位矩阵子宫内膜异位症药物市场供应商的绩效评估

FPNV定位矩阵是评估子宫内膜异位症药物市场供应商的重要工具。此矩阵允许业务组织根据供应商的商务策略和产品满意度评估供应商，从而做出符合其目标的明智决策。这四个象限使您能够清晰、准确地划分供应商，并确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析与建议，规划子宫内膜异位症治疗药物市场的成功之路

对于旨在加强其在全球市场的影响力的公司来说，对子宫内膜异位症治疗药物市场的策略分析至关重要。透过审查关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机，并取得长期成功。

本报告对市场进行了全面分析，涵盖关键重点领域：

1. 市场渗透率：对当前市场环境的详细审查、主要企业的广泛资料、对其在市场中的影响力和整体影响力的评估。

2. 市场开拓：辨识新兴市场的成长机会，评估现有领域的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监理核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点在于有望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，以帮助相关人员做出明智的决策：

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品、区隔市场和地区提供最佳投资机会？

3.塑造市场的主要技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 政府对妇女健康计画的承诺和支持，以增加子宫内膜异位症治疗的可近性
      • 提高子宫内膜异位症微创治疗的可用性和可及性
      • 提高患者对子宫内膜异位症较好治疗方法的认识与支持
      • 扩大远端医疗和数位健康平台以促进子宫内膜异位症管理
    • 抑制因素
      • 子宫内膜异位症治疗方法相关的经济障碍和高成本
      • 耻辱和缺乏认识导致子宫内膜异位症患者诊断和治疗的延误
    • 机会
      • 奈米技术标靶给药系统在子宫内膜异位症治疗的应用
      • 加大对子宫内膜异位症新治疗方法研发的投入
      • 扩大医疗保健政策以涵盖创新的子宫内膜异位症治疗方法和疗法
    • 任务
      • 全球监管合规挑战影响新子宫内膜异位症治疗的市场准入
      • 供应链中断导致药物短缺和子宫内膜异位症医疗管理成本增加
  • 市场区隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社群
    • 技术的
    • 合法地
    • 环境

第 6 章：按药物类型分類的子宫内膜异位症治疗市场

  • 促性腺激素分泌释放激素促效剂
  • 非类固醇消炎剂
  • 口服避孕药
  • 黄体素治疗

第七章子宫内膜异位症药物市场：依给药途径

  • 可注射的
  • 口服药物

第八章子宫内膜异位症治疗药物市场患者细分

  • 成人用
  • 老年病
  • 小儿科

第九章子宫内膜异位症治疗药物市场：依最终使用者分类

  • 诊所
  • 家庭护理设置
  • 医院

第十章北美和南美子宫内膜异位症治疗药物市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十一章亚太子宫内膜异位症药物市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十二章欧洲、中东和非洲子宫内膜异位症治疗药物市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十三章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
  • 战略分析和建议
Product Code: MRR-2B5802CFEB6F

The Endometriosis Drugs Market was valued at USD 2.54 billion in 2023, expected to reach USD 2.69 billion in 2024, and is projected to grow at a CAGR of 7.11%, to USD 4.11 billion by 2030.

The scope of the endometriosis drugs market encompasses the range of pharmaceutical treatments developed to manage pain and other symptoms associated with endometriosis, a condition where tissue similar to the uterine lining grows outside the uterus. These drugs are essential due to the chronic and often debilitating nature of endometriosis, affecting approximately 10% of women of reproductive age globally, according to figures from health organizations. The application of these drugs primarily focuses on reducing inflammation, alleviating pain, and moderating hormonal imbalances. Key end-users include hospitals, clinics, and homecare settings, where patients seek medical intervention for the condition's management. Crucial market growth influencers include increasing prevalence of endometriosis, heightened awareness and diagnosis rates, and advances in drug development technologies such as oral gonadotropin-releasing hormone antagonists. Additionally, government support and investment in women's health initiatives have opened new opportunities. Companies can capitalize by focusing on early detection technologies and personalized medicine approaches, offering potential productivity gains and patient satisfaction. However, limitations such as high drug costs, limited availability of non-invasive treatments, and potential side effects pose significant challenges. Furthermore, lack of awareness in emerging economies continues to restrict market penetration. Innovation areas ripe for exploration include developing bio-identical hormones with fewer side effects and leveraging digital health technologies for early diagnosis and treatment monitoring. Research into alternative therapies like immunomodulation and angiogenesis inhibitors may present further avenues for development. The nature of this market is competitive, with pharmaceutical giants investing in R&D while startups emerge with niche solutions. To stay competitive, companies should partner with academic institutions for cutting-edge research and maintain a patient-centric approach to drug development, ensuring accessibility and affordability of therapies.

KEY MARKET STATISTICS
Base Year [2023] USD 2.54 billion
Estimated Year [2024] USD 2.69 billion
Forecast Year [2030] USD 4.11 billion
CAGR (%) 7.11%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Endometriosis Drugs Market

The Endometriosis Drugs Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Government initiatives and support for women's health programs boosting endometriosis treatment availability
    • Increasing availability and accessibility of minimally invasive treatments for endometriosis
    • Rising patient awareness and advocacy for better endometriosis treatment options
    • Expansion of telemedicine and digital health platforms facilitating endometriosis management
  • Market Restraints
    • Financial barriers and high costs associated with endometriosis treatment regimens
    • Stigma and lack of awareness leading to delayed diagnosis and treatment in endometriosis patients
  • Market Opportunities
    • The application of nanotechnology for targeted drug delivery systems in endometriosis treatment
    • The increasing investment in research and development for novel endometriosis therapeutics
    • The expansion of healthcare policies to cover innovative endometriosis treatments and therapies
  • Market Challenges
    • Global regulatory compliance challenges affecting the market entry of new endometriosis treatments
    • Supply chain disruptions leading to drug shortages and increased costs in endometriosis healthcare management

Porter's Five Forces: A Strategic Tool for Navigating the Endometriosis Drugs Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Endometriosis Drugs Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Endometriosis Drugs Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Endometriosis Drugs Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Endometriosis Drugs Market

A detailed market share analysis in the Endometriosis Drugs Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Endometriosis Drugs Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Endometriosis Drugs Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Endometriosis Drugs Market

A strategic analysis of the Endometriosis Drugs Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Endometriosis Drugs Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, AbbVie Inc., Allergan Plc, AstraZeneca, Bayer AG, Bristol-Myers Squibb Company, Eli Lilly and Company, Endo International Plc, Ferring Pharmaceuticals, GlaxoSmithKline Plc, Janssen Pharmaceuticals, Inc., Johnson & Johnson, Merck & Co., Inc., Myovant Sciences, Novartis AG, Organon & Co., Pfizer Inc., Sanofi S.A., Takeda Pharmaceutical Company Limited, and Viatris Inc..

Market Segmentation & Coverage

This research report categorizes the Endometriosis Drugs Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Drug Type, market is studied across Gonadotropins Releasing Hormone Agonists, Nonsteroidal Anti-Inflammatory Drugs, Oral Contraceptive Pills, and Progestin Therapy.
  • Based on Route Of Administration, market is studied across Injectable and Oral Drugs.
  • Based on Patient Demographics, market is studied across Adult, Geriatric, and Pediatric.
  • Based on End-User, market is studied across Clinics, Homecare Settings, and Hospitals.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Government initiatives and support for women's health programs boosting endometriosis treatment availability
      • 5.1.1.2. Increasing availability and accessibility of minimally invasive treatments for endometriosis
      • 5.1.1.3. Rising patient awareness and advocacy for better endometriosis treatment options
      • 5.1.1.4. Expansion of telemedicine and digital health platforms facilitating endometriosis management
    • 5.1.2. Restraints
      • 5.1.2.1. Financial barriers and high costs associated with endometriosis treatment regimens
      • 5.1.2.2. Stigma and lack of awareness leading to delayed diagnosis and treatment in endometriosis patients
    • 5.1.3. Opportunities
      • 5.1.3.1. The application of nanotechnology for targeted drug delivery systems in endometriosis treatment
      • 5.1.3.2. The increasing investment in research and development for novel endometriosis therapeutics
      • 5.1.3.3. The expansion of healthcare policies to cover innovative endometriosis treatments and therapies
    • 5.1.4. Challenges
      • 5.1.4.1. Global regulatory compliance challenges affecting the market entry of new endometriosis treatments
      • 5.1.4.2. Supply chain disruptions leading to drug shortages and increased costs in endometriosis healthcare management
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Endometriosis Drugs Market, by Drug Type

  • 6.1. Introduction
  • 6.2. Gonadotropins Releasing Hormone Agonists
  • 6.3. Nonsteroidal Anti-Inflammatory Drugs
  • 6.4. Oral Contraceptive Pills
  • 6.5. Progestin Therapy

7. Endometriosis Drugs Market, by Route Of Administration

  • 7.1. Introduction
  • 7.2. Injectable
  • 7.3. Oral Drugs

8. Endometriosis Drugs Market, by Patient Demographics

  • 8.1. Introduction
  • 8.2. Adult
  • 8.3. Geriatric
  • 8.4. Pediatric

9. Endometriosis Drugs Market, by End-User

  • 9.1. Introduction
  • 9.2. Clinics
  • 9.3. Homecare Settings
  • 9.4. Hospitals

10. Americas Endometriosis Drugs Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Endometriosis Drugs Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Endometriosis Drugs Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2023
  • 13.2. FPNV Positioning Matrix, 2023
  • 13.3. Competitive Scenario Analysis
  • 13.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Abbott Laboratories
  • 2. AbbVie Inc.
  • 3. Allergan Plc
  • 4. AstraZeneca
  • 5. Bayer AG
  • 6. Bristol-Myers Squibb Company
  • 7. Eli Lilly and Company
  • 8. Endo International Plc
  • 9. Ferring Pharmaceuticals
  • 10. GlaxoSmithKline Plc
  • 11. Janssen Pharmaceuticals, Inc.
  • 12. Johnson & Johnson
  • 13. Merck & Co., Inc.
  • 14. Myovant Sciences
  • 15. Novartis AG
  • 16. Organon & Co.
  • 17. Pfizer Inc.
  • 18. Sanofi S.A.
  • 19. Takeda Pharmaceutical Company Limited
  • 20. Viatris Inc.

LIST OF FIGURES

  • FIGURE 1. ENDOMETRIOSIS DRUGS MARKET RESEARCH PROCESS
  • FIGURE 2. ENDOMETRIOSIS DRUGS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL ENDOMETRIOSIS DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL ENDOMETRIOSIS DRUGS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL ENDOMETRIOSIS DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL ENDOMETRIOSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL ENDOMETRIOSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL ENDOMETRIOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL ENDOMETRIOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL ENDOMETRIOSIS DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL ENDOMETRIOSIS DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL ENDOMETRIOSIS DRUGS MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL ENDOMETRIOSIS DRUGS MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. AMERICAS ENDOMETRIOSIS DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. AMERICAS ENDOMETRIOSIS DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. UNITED STATES ENDOMETRIOSIS DRUGS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 17. UNITED STATES ENDOMETRIOSIS DRUGS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC ENDOMETRIOSIS DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. ASIA-PACIFIC ENDOMETRIOSIS DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA ENDOMETRIOSIS DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. EUROPE, MIDDLE EAST & AFRICA ENDOMETRIOSIS DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. ENDOMETRIOSIS DRUGS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 23. ENDOMETRIOSIS DRUGS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. ENDOMETRIOSIS DRUGS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL ENDOMETRIOSIS DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL ENDOMETRIOSIS DRUGS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL ENDOMETRIOSIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. ENDOMETRIOSIS DRUGS MARKET DYNAMICS
  • TABLE 7. GLOBAL ENDOMETRIOSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL ENDOMETRIOSIS DRUGS MARKET SIZE, BY GONADOTROPINS RELEASING HORMONE AGONISTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL ENDOMETRIOSIS DRUGS MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL ENDOMETRIOSIS DRUGS MARKET SIZE, BY ORAL CONTRACEPTIVE PILLS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL ENDOMETRIOSIS DRUGS MARKET SIZE, BY PROGESTIN THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL ENDOMETRIOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL ENDOMETRIOSIS DRUGS MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL ENDOMETRIOSIS DRUGS MARKET SIZE, BY ORAL DRUGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL ENDOMETRIOSIS DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL ENDOMETRIOSIS DRUGS MARKET SIZE, BY ADULT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL ENDOMETRIOSIS DRUGS MARKET SIZE, BY GERIATRIC, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL ENDOMETRIOSIS DRUGS MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL ENDOMETRIOSIS DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL ENDOMETRIOSIS DRUGS MARKET SIZE, BY CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL ENDOMETRIOSIS DRUGS MARKET SIZE, BY HOMECARE SETTINGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL ENDOMETRIOSIS DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. AMERICAS ENDOMETRIOSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 24. AMERICAS ENDOMETRIOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 25. AMERICAS ENDOMETRIOSIS DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 26. AMERICAS ENDOMETRIOSIS DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 27. AMERICAS ENDOMETRIOSIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 28. ARGENTINA ENDOMETRIOSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 29. ARGENTINA ENDOMETRIOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 30. ARGENTINA ENDOMETRIOSIS DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 31. ARGENTINA ENDOMETRIOSIS DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 32. BRAZIL ENDOMETRIOSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 33. BRAZIL ENDOMETRIOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 34. BRAZIL ENDOMETRIOSIS DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 35. BRAZIL ENDOMETRIOSIS DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 36. CANADA ENDOMETRIOSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 37. CANADA ENDOMETRIOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 38. CANADA ENDOMETRIOSIS DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 39. CANADA ENDOMETRIOSIS DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 40. MEXICO ENDOMETRIOSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 41. MEXICO ENDOMETRIOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 42. MEXICO ENDOMETRIOSIS DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 43. MEXICO ENDOMETRIOSIS DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 44. UNITED STATES ENDOMETRIOSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 45. UNITED STATES ENDOMETRIOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 46. UNITED STATES ENDOMETRIOSIS DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 47. UNITED STATES ENDOMETRIOSIS DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 48. UNITED STATES ENDOMETRIOSIS DRUGS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 49. ASIA-PACIFIC ENDOMETRIOSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 50. ASIA-PACIFIC ENDOMETRIOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 51. ASIA-PACIFIC ENDOMETRIOSIS DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 52. ASIA-PACIFIC ENDOMETRIOSIS DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 53. ASIA-PACIFIC ENDOMETRIOSIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 54. AUSTRALIA ENDOMETRIOSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 55. AUSTRALIA ENDOMETRIOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 56. AUSTRALIA ENDOMETRIOSIS DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 57. AUSTRALIA ENDOMETRIOSIS DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 58. CHINA ENDOMETRIOSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 59. CHINA ENDOMETRIOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 60. CHINA ENDOMETRIOSIS DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 61. CHINA ENDOMETRIOSIS DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 62. INDIA ENDOMETRIOSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 63. INDIA ENDOMETRIOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 64. INDIA ENDOMETRIOSIS DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 65. INDIA ENDOMETRIOSIS DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 66. INDONESIA ENDOMETRIOSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 67. INDONESIA ENDOMETRIOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 68. INDONESIA ENDOMETRIOSIS DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 69. INDONESIA ENDOMETRIOSIS DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 70. JAPAN ENDOMETRIOSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 71. JAPAN ENDOMETRIOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 72. JAPAN ENDOMETRIOSIS DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 73. JAPAN ENDOMETRIOSIS DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 74. MALAYSIA ENDOMETRIOSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 75. MALAYSIA ENDOMETRIOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 76. MALAYSIA ENDOMETRIOSIS DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 77. MALAYSIA ENDOMETRIOSIS DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 78. PHILIPPINES ENDOMETRIOSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 79. PHILIPPINES ENDOMETRIOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 80. PHILIPPINES ENDOMETRIOSIS DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 81. PHILIPPINES ENDOMETRIOSIS DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 82. SINGAPORE ENDOMETRIOSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 83. SINGAPORE ENDOMETRIOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 84. SINGAPORE ENDOMETRIOSIS DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 85. SINGAPORE ENDOMETRIOSIS DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 86. SOUTH KOREA ENDOMETRIOSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 87. SOUTH KOREA ENDOMETRIOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 88. SOUTH KOREA ENDOMETRIOSIS DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 89. SOUTH KOREA ENDOMETRIOSIS DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 90. TAIWAN ENDOMETRIOSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 91. TAIWAN ENDOMETRIOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 92. TAIWAN ENDOMETRIOSIS DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 93. TAIWAN ENDOMETRIOSIS DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 94. THAILAND ENDOMETRIOSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 95. THAILAND ENDOMETRIOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 96. THAILAND ENDOMETRIOSIS DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 97. THAILAND ENDOMETRIOSIS DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 98. VIETNAM ENDOMETRIOSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 99. VIETNAM ENDOMETRIOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 100. VIETNAM ENDOMETRIOSIS DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 101. VIETNAM ENDOMETRIOSIS DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 102. EUROPE, MIDDLE EAST & AFRICA ENDOMETRIOSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 103. EUROPE, MIDDLE EAST & AFRICA ENDOMETRIOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 104. EUROPE, MIDDLE EAST & AFRICA ENDOMETRIOSIS DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 105. EUROPE, MIDDLE EAST & AFRICA ENDOMETRIOSIS DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 106. EUROPE, MIDDLE EAST & AFRICA ENDOMETRIOSIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 107. DENMARK ENDOMETRIOSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 108. DENMARK ENDOMETRIOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 109. DENMARK ENDOMETRIOSIS DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 110. DENMARK ENDOMETRIOSIS DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 111. EGYPT ENDOMETRIOSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 112. EGYPT ENDOMETRIOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 113. EGYPT ENDOMETRIOSIS DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 114. EGYPT ENDOMETRIOSIS DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 115. FINLAND ENDOMETRIOSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 116. FINLAND ENDOMETRIOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 117. FINLAND ENDOMETRIOSIS DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 118. FINLAND ENDOMETRIOSIS DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 119. FRANCE ENDOMETRIOSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 120. FRANCE ENDOMETRIOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 121. FRANCE ENDOMETRIOSIS DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 122. FRANCE ENDOMETRIOSIS DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 123. GERMANY ENDOMETRIOSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 124. GERMANY ENDOMETRIOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 125. GERMANY ENDOMETRIOSIS DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 126. GERMANY ENDOMETRIOSIS DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 127. ISRAEL ENDOMETRIOSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 128. ISRAEL ENDOMETRIOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 129. ISRAEL ENDOMETRIOSIS DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 130. ISRAEL ENDOMETRIOSIS DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 131. ITALY ENDOMETRIOSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 132. ITALY ENDOMETRIOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 133. ITALY ENDOMETRIOSIS DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 134. ITALY ENDOMETRIOSIS DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 135. NETHERLANDS ENDOMETRIOSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 136. NETHERLANDS ENDOMETRIOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 137. NETHERLANDS ENDOMETRIOSIS DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 138. NETHERLANDS ENDOMETRIOSIS DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 139. NIGERIA ENDOMETRIOSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 140. NIGERIA ENDOMETRIOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 141. NIGERIA ENDOMETRIOSIS DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 142. NIGERIA ENDOMETRIOSIS DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 143. NORWAY ENDOMETRIOSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 144. NORWAY ENDOMETRIOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 145. NORWAY ENDOMETRIOSIS DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 146. NORWAY ENDOMETRIOSIS DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 147. POLAND ENDOMETRIOSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 148. POLAND ENDOMETRIOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 149. POLAND ENDOMETRIOSIS DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 150. POLAND ENDOMETRIOSIS DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 151. QATAR ENDOMETRIOSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 152. QATAR ENDOMETRIOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 153. QATAR ENDOMETRIOSIS DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 154. QATAR ENDOMETRIOSIS DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 155. RUSSIA ENDOMETRIOSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 156. RUSSIA ENDOMETRIOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 157. RUSSIA ENDOMETRIOSIS DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 158. RUSSIA ENDOMETRIOSIS DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 159. SAUDI ARABIA ENDOMETRIOSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 160. SAUDI ARABIA ENDOMETRIOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 161. SAUDI ARABIA ENDOMETRIOSIS DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 162. SAUDI ARABIA ENDOMETRIOSIS DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 163. SOUTH AFRICA ENDOMETRIOSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 164. SOUTH AFRICA ENDOMETRIOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 165. SOUTH AFRICA ENDOMETRIOSIS DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 166. SOUTH AFRICA ENDOMETRIOSIS DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 167. SPAIN ENDOMETRIOSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 168. SPAIN ENDOMETRIOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 169. SPAIN ENDOMETRIOSIS DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 170. SPAIN ENDOMETRIOSIS DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 171. SWEDEN ENDOMETRIOSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 172. SWEDEN ENDOMETRIOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 173. SWEDEN ENDOMETRIOSIS DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 174. SWEDEN ENDOMETRIOSIS DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 175. SWITZERLAND ENDOMETRIOSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 176. SWITZERLAND ENDOMETRIOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 177. SWITZERLAND ENDOMETRIOSIS DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 178. SWITZERLAND ENDOMETRIOSIS DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 179. TURKEY ENDOMETRIOSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 180. TURKEY ENDOMETRIOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 181. TURKEY ENDOMETRIOSIS DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 182. TURKEY ENDOMETRIOSIS DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 183. UNITED ARAB EMIRATES ENDOMETRIOSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 184. UNITED ARAB EMIRATES ENDOMETRIOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 185. UNITED ARAB EMIRATES ENDOMETRIOSIS DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 186. UNITED ARAB EMIRATES ENDOMETRIOSIS DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 187. UNITED KINGDOM ENDOMETRIOSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 188. UNITED KINGDOM ENDOMETRIOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 189. UNITED KINGDOM ENDOMETRIOSIS DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 190. UNITED KINGDOM ENDOMETRIOSIS DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 191. ENDOMETRIOSIS DRUGS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 192. ENDOMETRIOSIS DRUGS MARKET, FPNV POSITIONING MATRIX, 2023